Marker for detecting highly pathogenic influenza virus and use thereof
Provided are a marker for detecting a highly pathogenic influenza virus including a protein mutant prepared by substituting the amino acids 68 and 69 of a PB1-F2 protein, a composition for detecting a highly pathogenic virus including an agent for measuring the protein mutant, and a detection kit including the same, a method for detecting a highly pathogenic virus including measuring the protein mutant, an antiviral composition against influenza A virus including an inhibitor of binding between a PB1-F2 protein in which the amino acids 68 and 69 are substituted and DDX3, and a method for screening an antiviral substance against influenza A virus.
1. A method for detecting a highly pathogenic virus, comprising:
measuring whether an unknown virus has a PB1-F2 protein mutant, and
determining an unknown virus measured to have the PB1-F2 protein mutant to be a highly pathogenic virus,
wherein the PB1-F2 protein mutant consists of the amino acid sequence of SEQ ID NO: 1 wherein the isoleucine and leucine at positions 68 and 69 are substituted with threonine and proline, respectively.
2. The method of claim 1 , wherein the protein mutant consists of the amino acid sequence of SEQ ID NO: 2.
3. The method of claim 1 , wherein the virus is an influenza virus.
4. A method for screening an antiviral substance against influenza A virus, comprising:
(a) in vitro treating cells with a candidate substance;
(b) measuring binding between DDX3 and a PB1-F2 protein in the cells;
(c) selecting a substance measured to inhibit the binding between the DDX3 and the PB1-F2 protein, compared to a group which is not treated with a candidate substance; and
(d) determining the selected substance to be an antiviral substance against influenza A virus,
wherein the PB1-F2 protein mutant consists of the amino acid sequence of SEQ ID NO: 1 wherein the isoleucine and leucine at positions 68 and 69 are substituted with threonine and proline, respectively.
5. The method of claim 4 , wherein the candidate substance is selected from the group consisting of a nucleic acid, a compound, a microbial culture medium or extract, a natural substance extract, a peptide, a substrate analog, an aptamer, and an antibody.
6. The method of claim 5 , wherein the nucleic acid is selected from the group consisting of siRNA, shRNA, microRNA, antisense RNA, an aptamer, a locked nucleic acid (LNA), a peptide nucleic acid (PNA), and a morpholino.
7. The method of claim 4 , wherein step (b) is executed using a method selected from the group consisting of western blotting, immunoprecipitation, immunohistochemistry, and immunofluorescence.
8. The method of claim 4 , wherein the PB1-F2 protein consists of the amino acid sequence of SEQ ID NO: 2.